AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04550286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Students will be given general advice on how to organize their exam preparation environment and behavior to improve their overall learning performance (e.g., organization of materials for exam preparation, pauses during exam preparation).
Study NCT01218295 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirotiger®
Description: training session :10 minutes twice a day X 4 weeks
Study NCT03739697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: spontaneous breathing
Description: spontaneous breathing during induction of anesthesia in infants
Study NCT01579110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levamisole
Description: Levamisole 2.5mg/kg(every other day) over six months.~Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Study NCT01579110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
Study NCT02315053 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low dose FDG PET/CT 5 x.
Description: Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
Study NCT02243761 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBT Based Skills Groups for Families
Description: 12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
Study NCT02106637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: drug will be initiated during hospitalization and continued for 12 weeks following discharge
Study NCT02106637 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04326153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Preoperative:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of two cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total~Postoperative:~Patients began to receive postoperative adjuvant treatment within 21-60 days after the operation. Specific medication plan:~Sintilimab: 200mg QD, one cycle every 21 days, the first day of each cycle, a total of 8 cycles.~Albumin paclitaxel: 135mg / m2 QD, 1 cycle every 21 days, 1 day and 8 days of each cycle, 2 cycles in total.~Carboplatin: AUC 5mg QD, one cycle every 21 days, two cycles in total.
Study NCT00225277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Study NCT00225277 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
Study NCT02569320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDAC Inhibitor AR-42
Description: Given PO
Study NCT02569320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02569320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO
Study NCT01448525 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bimatoprost ophthalmic solution 0.03%
Description: One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Study NCT01448525 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
Study NCT05342116 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nestle Preload
Description: 1 sachet of Preload (50g) diluted with 400ml of water, to be consumed 2 to 4 hours prior to the endoscopy.
Study NCT05342116 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: 400ml of water to be consumed 2 to 4 hours prior to the endoscopy.
Study NCT00981825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Whole mouth brushing for 7 days
Study NCT01469975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 1
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
Study NCT01469975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 2
Description: Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
Study NCT01469975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y level 3
Description: Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.~This third dose level evaluation will be based on safety and preliminary efficacy data.
Study NCT01448603 — intervention group
Intervention type: BIOLOGICAL
Intervention: Placebo
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
Study NCT01448603 — intervention group
Intervention type: BIOLOGICAL
Intervention: ToleroMune Ragweed
Description: No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
Study NCT02046798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: oral
Study NCT02923609 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cell Therapy
Description: Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
Study NCT03411928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tracheolator
Description: 'Tracheolator' non-occlusive tracheal dilation balloon manufactured by Disa Life Sciences, Cape Town, South Africa.
Study NCT01836991 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgery
Study NCT01836991 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT01803776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle counseling
Description: The physical activity and dietary intervention is based on the Finnish physical activity and dietary recommendations. The children and their parents in the intervention group undergo individualized and family-based physical activity and dietary intervention between the baseline and 2-year follow-up examinations. The children and their parents meet a physical activity specialist and a nutritionist who give detailed and individualized instructions on health promoting physical activity and diet at months 0, 1.5, 3, 6, 12, and 18 with a specific topic at each visit. Between the 2-year follow-up and 8-year follow-up examinations, the intervention continues with yearly physical activity and dietary counseling sessions. The children in the intervention group, particularly those who do not attend organized sports or exercise, will also be encouraged to participate in after-school exercise clubs organized by trained exercise instructors of the study.
Study NCT02331849 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: High resolution manometry (HRM)
Description: High resolution manometry of the esophagus
Study NCT00899704 — intervention group
Intervention type: GENETIC
Intervention: microarray analysis
Study NCT00899704 — intervention group
Intervention type: GENETIC
Intervention: allele-specific oligonucleotide real-time quantitative polymerase chain reaction
Study NCT00899704 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Study NCT03479944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLACS
Description: Femtosecond laser assisted cataract surgery consisting of LenSx® and Centurion® combination
Study NCT03479944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual conventional surgery
Description: Removal of cataractous lens by phacoemulsification
Study NCT03479944 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CENTURION® Vision System
Description: Phacoemulsification aspiration platform for use during cataract surgery
Study NCT03479944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CENTURION® Vision System
Description: Phacoemulsification aspiration platform for use during cataract surgery
Study NCT03479944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LenSx®
Description: Femtosecond laser system used for continuous curvilinear capsulorhexis (CCC) and lens fragmentation during cataract surgery
Study NCT05631782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shenkang decoction
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
Study NCT05631782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenkang decoction
Description: Given Shenkang decoction on the basis of the above treatment. Shenkang decoction prescription: 15 g of semen cuscutae, herba epimedii and pericarpium arecae. 20 g of Eucommia ulmoides Oliv., radix astragali, codonopsis pilosula, salvia miltiorrhiza, tuckahoe, atractylodes macrocephala, Chinese yam, honeysuckle, polyporus umbellatus and dandelion. 15 g of safflower. 12 g of processed Fuzi. 10 g of Radix phytolaccae and sage. Golden cherry son 20 g and puzzle kernel 15 g were added to patients with frequent proteinuria and nocturia took. Yellow cypress 15 g was added to patients with damp-heat in lower-Jiao. The decoction pieces were purchased from the Traditional Chinese Medicine and Pharmacy Department of the First People's Hospital of Zunyi City. They were decocted by computer automatic decocting machine (model) and divided into 150 mL / bag, taken orally, once in the morning, noon and evening, 3 times / day, 1 bag / time, one pair a day. Treatment lasted for 10 - 14 days.
Study NCT01973335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy with acetazolamide and low-dose loop diuretics
Description: * Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
Study NCT01973335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High-dose loop diuretics
Description: * Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
Study NCT01973335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose loop diuretics
Description: * Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.~* Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.~* If diuresis \<1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.~In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option.
Study NCT01973335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upfront therapy with oral spironolactone
Description: Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.~Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not.
Study NCT01669785 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
Study NCT01669785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
Study NCT01669785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Group B
Description: Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
Study NCT03423966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone Pedometer App
Description: Installation of the free pedometer app and explanation to participants to target 10000 steps per day. The intent is not the accuracy of the pedometer but the motivation especially to a community yet to harness the full potentials of the mobile phone technology
Study NCT02466607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RETeval color flicker ERG
Description: Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
Study NCT02466607 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RETeval dilated versus un-dilated flicker ERG
Description: Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
Study NCT02466607 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pupil dilation
Description: Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
Study NCT03750409 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Helmet
Description: The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
Study NCT03750409 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Helmet
Description: The portable device covers the head and weighs about 3.5 lb., and is made of light-weight, durable plastic, it is placed on the head with eye panels facing forward. Elastic straps holding the arrays together easily expand to conform to each subjects' head. Patients may notice slight warming of scalp after usage. This warming effect is similar to wearing a regular motorcycle helmet for a similar duration.
Study NCT01726621 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Medtronic MiniMed 620G or 640G Insulin Pump
Description: Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
Study NCT00552032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate nasal spray
Description: Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
Study NCT00552032 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
Study NCT03299894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: systematic calculation of qSOFA
Description: calculation of qSOFA for each patient
Study NCT03595267 — intervention group
Intervention type: OTHER
Intervention: Point-of-care screening
Description: After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a closed loop system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations.
Study NCT02195726 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
Study NCT02195726 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
Study NCT00426660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maraviroc
Description: The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
Study NCT02565706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WIC Fresh Start Program
Description: The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
Study NCT02565706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIC Fresh Start Program
Description: The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
Study NCT02565706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Existing Online Health Education
Description: Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
Study NCT03755518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEDRATINIB
Description: A potent and selective inhibitor of JAK2 kinase activity
Study NCT04030325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sequential Personalized Feedback Intervention Delivery
Description: Sequential PFI delivery over 3 weeks after baseline survey